A prodrug is a strategic innovation in biopharmaceutics designed to enhance the absorption, distribution, and delivery of therapeutic agents within the human body. This ingenious approach involves the administration of an inactive precursor that undergoes a biotransformation to the active drug form, either enzymatically or non-enzymatically, after administration.
In biopharmaceutics, prodrugs address challenges such as poor solubility, stability, or limited bioavailability of certain drugs. By converting the active compound into a prodrug, these limitations can be overcome, leading to improved therapeutic outcomes. Prodrugs also allow for targeted drug delivery, minimizing potential side effects and enhancing patient compliance.
The versatility of prodrugs spans various drug classes, including analgesics, antivirals, and anticancer agents. This approach exemplifies the continual evolution of pharmaceutical science in optimizing drug performance and patient well-being. As a key player in the realm of biopharmaceutics, prodrugs pave the way for more efficient and precise drug delivery strategies in the field of medicine.
Yong Xiao Wang
Albany Medical College, United States
Consolato M Sergi
Universities of Alberta and Ottawa, Canada
Vladlen Slepak
University of Miami Miller School of Medicine, United States
Andreas M Papas
Antares Health Products, United States
Axel H Schonthal
University of Southern California, United States
Bernd Blobel
University of Regensburg, Germany
Gurpreet Singh
IQVIA, United Kingdom
Rassa Pegahi
UPSA, France
Tanuja Tummala
Harrisburg University of Science and Technology, United States
Natassa Pippa
University of Athens, GreeceSubmit your abstract Today
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Analytical strategies for solid-state forms in drug development
Maria Cristina Gamberini, University of Modena e Reggio Emilia, Italy
Title : Understanding drug transport in plasma: The role of protein binding
Saad Tayyab, UCSI University, Malaysia
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Search for novel biomarkers and therapeutic targets for inflammatory disease
Madhav Bhatia, University of Otago, New Zealand
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through de-sign-inspired biotech- & biopharma-driven applications and upgraded business mar-keting to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Design and evaluation of exo-itc: A bilayer fibrous system for controlled exosome delivery in dermatological applications
Luis Jesus Villarreal Gomez, FCITEC - Universidad Autónoma de Baja California, Mexico
Title : Abuse-deterrent dosage form technique utilizing a fusion of innovative pharmaceuticals and ion exchange resin
Bhupendra Gopalbhai Prajapati, Parul University, India
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia